User:Jcamp2023/sandbox

Welcome to your sandbox!
This is place to practice clicking the "edit" button and practice adding references (via the citation button). Please see Help:My_sandbox or contact User_talk:JenOttawa with any questions.

Link: Project Homepage and Resources


 * Note: Please use your sandbox to submit assignment # 3 by pasting it below. When uploading your improvements to the article talk page please share your exact proposed edit (not the full assignment 3).


 * Talk Page Template: CARL Medical Editing Initiative/Fall 2019/Talk Page Template

Proposed changes to the Hodgkin's Lymphoma Article:

Distinction of nodular lymphocyte predominant Hodgkin lymphoma from Classical Hodgkin Lymphoma. I will write a sentence or two on the differences between the subtypes and the pathology. Have WHO citation as well as another review article.

Assignment # 2
Nodular lymphocyte-predominant Hodgkin lymphoma

Citation: Eichenauer, D. A., & Engert, A. (2017). Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology, (1), 324–328. doi: 10.1182/asheducation-  2017.1.324

1)       How you searched for a source (search strategy – where you went to find it).

I used PubMed to search for the topic of nodular lymphocyte predominant Hodgkin and narrowed the search to English Review Articles from 2012 onwards. If I added the word lymphoma to the search, I would mostly get Hodgkin lymphoma results, and not the subset of lymphocyte predominant Hodgkin lymphoma that I was looking for. This strategy narrowed down the possible articles from 979 to 46. I still had to sift through the titles in order to find appropriate, specific articles, as many were for the overarching disease of Hodgkin Lymphoma.

2)       What potential sources were identified and considered (give examples of 1 or 2).


 * 1) Bose, S., Ganesan, C., Pant, M., Lai, C., & Tabbara, I. A. (2013). Lymphocyte-predominant Hodgkin Disease. American Journal of Clinical Oncology, 36(1), 91–96. doi: 10.1097/coc.0b013e31820dbc2c
 * 2) Goel, A., F. Wen, A. Patel, M. Devabhaktuni, M. Grossbard (2014). Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment. Clinical Lymphoma, Myeloma & Leukemia, 14(4), 261-270 doi: 10.1016/j.clml.2014.01.006

3)       Why the source was chosen (what made it better than other choices).

I chose the Eichenauer and Engert article as it was slightly more recent and the writing style seemed to make things easier to understand. It also had a ‘future directions’ section which appropriately outlined avenues that future research might take.

4)       List at least three reasons why the source that was selected meets Wikipedia’s reliable medical sources (MEDRS) criteria.

It is a secondary source (systematic review), it is up-to-date (less than 5 years old) and seemed to be from an unbiased source (the American Society for Hematology).

5)       How do you plan to use the source for improving the article?

I plan on using the information from this source to clarify the difference between Classic Hodgkin Lymphoma (which the Wikipedia article mainly focuses on) and the rarer nodular lymphocyte predominant Hodgkin lymphoma. It will be one or two sentences to describe this subset of the disease and it’s pathology.

Assignment # 3
Proposed Changes:

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is another subtype of Hodgkin lymphoma distinct from Classical Hodgkin lymphoma and is characterized by the presence of popcorn cells which express CD20. Due to these differences, among others, NLPHL is often treated differently from Classical HL, including using Rituximab in combination with AVBD chemotherapy, though individual cases vary and clinical trials are ongoing.

****** NLPHL is different from CHL in many ways. I feel arranging the sentence in this way puts too much emphasis on popcorn cells, which is an important and distinctive feature when comparing to CHL but not the one. I would rearrange the first sentence as follow:

Nodulary lymphocyte predominant Hodgkin lymphoma (NLPHL) is another subtype of Hodgkin lymphoma distinct from Classic Hodgkin lymphoma and is characterized by the presence of popcorn cells which express CD20.

I would also put a link to rituximab because the general public likely does not know what it is and why using it for CD20+ lymphomas.

********

The presence of popcorn cells, which express CD20+, in nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) distinguishes it pathologically from classical Hodgkin Lymphoma (HL).

Rationale for Proposed Change:

The current Wikipedia article does not clearly mention the differences between classical HL and NLPHL. This distinction needs to be made as most of the information on the Wikipedia page is about Classical HL, as NLPHL has its own page. Expressly stating the differences between these two subtypes is important as treatment and prevalence varies. This information has come from the World Health Organization (WHO) textbook with information on haematopoietic diseases as well as a Mayo Clinic Preceedings which is a part of Continuing Medical Education (CME).

Critique of Source:

The WHO textbook is a tertiary source which has recent information on haematopoietic tumours (published 2017, 4th edition). This is a trusted source which compiles known knowledge from different sources into one comprehensive source. The Mayo Clinic report was approved for use under the CME. As well, the author of the Mayo Clinic report was required to have ACCME accreditation and ensure "balance, independence, objectivity and scientific rigor" of the study. There were also editors, both physicians and non-physicians, who had no financial relationship with industry which increases the trust in the source. One source of bias is that the author (Dr. Ansell), received research funding from Bristol-Myers Squibb, a company that develops medications for patients with serious diseases, as well as Seattle Genetics.